0000000000811957

AUTHOR

Kedan Lin

showing 1 related works from this author

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

2020

Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules. Patients and methods The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and …

Male0301 basic medicinemedicine.medical_specialtyMaximum Tolerated Dosemedicine.medical_treatmentCàncer - Quimioteràpia:Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]GastroenterologyAKT inhibitorPiperazinesMedicaments antineoplàstics - Efectes secundaris:neoplasias [ENFERMEDADES]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy Protocols:Other subheadings::Other subheadings::/adverse effects [Other subheadings]medicineadvanced cancerHumansEnzalutamide:terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Adverse effectChemotherapybusiness.industryHematologyphase I:Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Oxaliplatin:Neoplasms [DISEASES]Pyrimidines030104 developmental biologyOncologyDocetaxelTolerabilityPaclitaxelchemistryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisbusinessmedicine.drugAnnals of Oncology
researchProduct